Reinvention of chemotherapy: drug conjugates and nanoparticles.

Details

Serval ID
serval:BIB_303295901F71
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Reinvention of chemotherapy: drug conjugates and nanoparticles.
Journal
Current Opinion In Oncology
Author(s)
Nguyen-Ngoc T., Raymond E.
ISSN
1531-703X (Electronic)
ISSN-L
1040-8746
Publication state
Published
Issued date
2015
Peer-reviewed
Oui
Volume
27
Number
3
Pages
232-242
Language
english
Notes
Publication types: Journal Article Publication Status: ppublish Document Type: Review
Abstract
PURPOSE OF REVIEW: Recent advances in nanotechnology have addressed some of the issues related to lack of selectivity and nonspecific toxicities associated with conventional chemotherapy. Nanoparticles are therapeutic carriers that can be fine tuned for specific application and for passive or active tumor targeting.
RECENT FINDINGS: Although the nanoparticle field is rapidly expanding, there are to date only six nanoparticle-based drug delivery platforms and two antibody-drug conjugates that are clinically approved for cancer therapy. Here, we review the clinical data of liposomal anthracyclines, nanoparticle formulations of paclitaxel and trastuzumab emtansine. We then briefly comment on efficacy and safety issues of nanoparticles, as well as on the next-generation nanoparticles for cancer therapy.
SUMMARY: The emerging development of cancer nanotechnology offers the opportunity of reinvestigating the potential of cytotoxic agents, improving tumor targeting and drug delivery, leading to better safety profile and antitumor activity. Adding specificity to nanoparticles may allow personalization of cancer therapy using chemotherapy.
Pubmed
Web of science
Create date
11/05/2015 12:18
Last modification date
20/08/2019 13:14
Usage data